- Details
- Description
-
Packaging Size56T/bottle
-
Strength120mg
-
CompositonSotorasib
-
TreatmentKRAS p.G12C Mutation non-small cell lung cancer (NSCLC)
-
FormTablet
-
BrandSOTOLDX
-
Quantity Unit120mg*56T/bottle
-
ManufacturerBIGBEAR Pharma,Laos PDR
Sotorasib is in a class of medications called KRAS inhibitors. It works by blocking the action of the abnormal protein that signals cancer cells to multiply.
Non-Small Cell Lung Cancer
Indicated for KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) in adults who have received ≥1 prior systemic therapy
960 mg PO qDay
Continue until disease progression or unacceptable toxicity
Dosage Modifications
Dosage reduction levels for adverse reactions
- First dose reduction: 480 mg qDay
- Second dose reduction: 240 mg qDay
- Unable to tolerate 240 mg qDay: Discontinue